RecruitingRecruiting
A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Crohn Disease on Advanced Therapies
NCT06890637 · All India Institute of Medical Sciences
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Efficacy of Microbiome Manipulation Strategies (Fecal Microbial Transplant or Crohns Disease Exclusion Diet or Both) With Advanced Therapies (BiOlOgics and Small Molecules) to Break the Therapeutic Ceiling in Active Crohns Disease (BOOST-CD): A Multicenter Double Blind Factorial Randomized Controlled Trial
About this study
This is a multicenter, double-blind, factorial randomized controlled trial (RCT) evaluating the efficacy of microbiome manipulation strategies in patients with active Crohn's Disease (CD) undergoing advanced therapy (biologics or small molecules). The study will be conducted across six clinical centers in India, with an additional center designated for microbiome analysis.
Randomization and Blinding:
Randomization: Centralized, computer-generated randomization using permuted blocks of 8, 12, and 16 to ensure equal distribution across intervention arms.
Stratification: Not more than 1/3rd patients should be biological therapy exposed
Blinding:
The blinded team includes patients and principal investigators. Endoscopists administering FMT/sham FMT and dietitians providing dietary counseling will be unblinded
Sham-Control Methods:
FMT Sham: Sterile clean water infusions via colonoscopy. Diet Sham: Dietary counseling without any modification
Intervention Arms:
Patients are randomized into one of four treatment groups:
FMT + CDED + Advanced Therapy (Group A) FMT + Sham Diet + Advanced Therapy (Group B) Sham FMT + CDED + Advanced Therapy (Group C) Sham FMT + Sham Diet + Advanced Therapy (Group D)
Fecal Microbiota Transplantation (FMT):
FMT Route: Administered via colonoscopy.
FMT Schedule:
Induction Phase: Weeks 0, 2, and 6. Maintenance Phase: Every 8 weeks (weeks 10, 18, 26, 34, 42) for responders.
Preparation:
Donor Selection: Multi-donor approach with prescreening FMT Processing: 50 g stool freshly prepared and instilled within 4 hours.
Delivery Locations:
Week 0 (Bowel Preparation): Right colon/terminal ileum. Weeks 2 and 6 (No Bowel Preparation): Left colon. Crohn's Disease Exclusion Diet (CDED)
Diet Structure:
Induction Phase (Weeks 0-6): Elimination of specific pro-inflammatory dietary components.
Maintenance Phase (Weeks 6-48): Gradual reintroduction of certain food groups. Monitoring: Adherence tracked using the IBD NutriCare app, diet recall logs, and DietCal software.
Sham Diet: Patients follow a standard healthy diet with general dietary counseling.
Assessments and Data Collection Baseline Assessments (Week 0) Clinical Data: Crohn's Disease Activity Index (CDAI), stool frequency, rectal bleeding, and symptom tracking.
Laboratory Tests:
Hemogram, renal/liver function tests, blood glucose. Inflammatory Markers: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fecal calprotectin (FCP).
Microbiome Analysis: Stool samples stored at -80°C for sequencing.
Endoscopic Evaluation:
Scoring: Simple Endoscopic Score for CD (SES-CD). Blinded Central Review: Videos assessed by two independent readers; discrepancies adjudicated by a third reader.
Histology: Biopsies analyzed using DCA score (Distribution Chronicity and Activity).
Follow-up Assessments
Visit Schedule:
Induction Phase: Weeks 2, 4, 6, and 10. Maintenance Phase: Every 8 weeks (weeks 18, 26, 34, 42, and 48). Clinical Assessments: CDAI, PRO2 symptom tracking, medication adherence checks. Endoscopy: Week 10 and Week 48; central scoring of videos. Diet Adherence: Assessed at weeks 2, 4, 6, and 10, then every 8 weeks. Microbiome Sampling: Stool samples collected at weeks 10 and 48. Safety Monitoring and Adverse Events
Adverse Event (AE) Classification:
CTCAE Grading (Grade 1-5) for treatment-related AEs. Serious Adverse Events (SAEs): Hospitalization, life-threatening events, or disability.
Safety Monitoring Plan:
Pre-procedural safety checks for each FMT session. Immediate post-FMT monitoring (48 hours). Late safety assessments (14 days post-FMT, then every visit). Unblinding Procedure: Allowed only for SAE management with DSMB approval. Data Management and Statistical Analysis
Electronic Data Capture (EDC):
Platform: REDCap database with tiered access permissions. Audit Trails: Secure logs of data entry and modification.
Dietary Data Processing:
IBD NutriCare app logs converted into macronutrient composition reports. Adherence scoring based on 80% compliance threshold.
Microbiome Data Processing:
Samples sequenced at IIIT-Delhi, analyzed for diversity indices and metabolic pathways.
Statistical Plan:
Primary Analysis: Intention-to-treat (ITT) and per-protocol (PP) analyses. Longitudinal Modeling: Mixed-effects models for repeated measures.
Effect Size Estimation:
Sample size: 168 patients (42 per arm).
Eligibility criteria
Inclusion Criteria:
1. Patients with active Crohn disease in whom FMT is feasible
2. Active Crohn's disease who are candidates for advanced therapy (steroid refractory, Immunomodulator intolerant or refractory and moderately severe disease at the time of inclusion) or patients who have an intolerance to or have lost response to advanced therapies must have had their last treatment at least five half-lives prior randomization.
3. Aged between 18-75 years
4. CDAI greater than 150 and/or SES-CD equal or greater than 6 (or equal or greater than 4 if isolated ileal disease)
Exclusion Criteria:
1. Patients in remission (CDAI less than 150)
2. Stricturing disease (non-passable stricture) in whom FMT is not feasible
3. Fistulising phenotype or Perianal fistula or abscess
4. Isolated L4 disease
5. Active TB or Sepsis
6. Pregnant or lactating women
7. Patients with co-morbidities like CAD/CLD/CKD
8. Previous surgery for CD
9. Declining consent or not willing for FMT or diet advice
10. Patients with current or recent history of clinically severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, or neurological disease.
11. Positive assay or stool culture for pathogens (ova and parasite examination, bacteria) or positive test for Clostridioides difficile toxin at screening#
12. Patients infected with human immunodeficiency virus (HIV) #The patients with positive assay will be treated appropriately and tests will be repeated.
Those with negative assay and persistent activity will be included in the study
Study design
Enrollment target: 168 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2025-03-15
Estimated completion: 2028-03-15
Last updated: 2025-04-04
Interventions
Other: Fecal Microbial TransplantationOther: Crohns Disease Exclusion DietOther: Sham transplantationOther: Sham DietOther: Advanced therapy
Primary outcomes
- • Proportion of patients with clinical remission and endoscopic response at week 10 (10 weeks)
- • Proportion of patients with clinical remission and endoscopic remission at week 10 (48 weeks)
Sponsor
All India Institute of Medical Sciences · other
Contacts & investigators
ContactProf Vineet Ahuja, DM Gastroenterology · contact · vineet.aiims@gmail.com · +91-9810707170
ContactDr Himanshu Narang, DM Gasteroentrology · contact · h92narang@gmail.com · +91-8800316504
InvestigatorProf Vineet Ahuja, DM Gastroenterology · principal_investigator, Department of Gastroenterology, AIIMS, New Delhi
All locations (6)
Department of Gastroenterology, Lisie HospitalNot Yet Recruiting
Kochi, Kerala, India
Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, SionNot Yet Recruiting
Mumbai, Maharashtra, India
Department of Gastroenterology and Human Nutrition, All India Institute of Medical SciencesRecruiting
New Delhi, National Capital Territory of Delhi, India
Department of Gastroenterology, Dayanand Medical CollegeNot Yet Recruiting
Ludhiana, Punjab, India
Department of Gastroenterology, Institute of Medical SciencesNot Yet Recruiting
Varanasi, Uttar Pradesh, India
Department of Gastroentrology, Postgraduate Institute of Medical Education and ResearchNot Yet Recruiting
Chandigarh, India